HUMA - Humacyte, Inc.

QQQ $ 623.16 $ -1.68 (-0.27 %)

DIA $ 482.05 $ 1.51 (0.31 %)

SPY $ 684.40 $ -0.39 (-0.06 %)

TLT $ 89.98 $ 0.03 (0.03 %)

GLD $ 379.76 $ -0.31 (-0.08 %)

Previous Close

$ 1.28

Open

$ 1.40

Bid

$ 1.38 x 100

Ask

$ 1.39 x 2,705

Day's Range

$ 1.38 - $ 1.43

52 Week Range

$ 1.15 - $ 6.77

Volume

5,139,112

Average Volume

Market Cap

202.72M

Beta (5Y Monthly)

$ 1.92

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-08-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-12-2023	03-31-2023	10-Q
11	03-24-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-13-2022	03-31-2022	10-Q
15	03-29-2022	12-31-2021	10-K
16	11-15-2021	09-30-2021	10-Q
17	08-16-2021	06-30-2021	10-Q
18	05-17-2021	03-31-2021	10-Q
19	02-16-2021	12-31-2020	10-K
20	11-13-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Humacyte Q3 EPS $(0.11) Beats $(0.16) Esti...
11/12/2025 12:08:35

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
11/12/2025 12:05:51

Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

Insights Ahead: Humacyte's Quarterly Earnings
11/11/2025 18:04:40

D. Boral Capital Maintains Buy on Humacyte...
11/10/2025 18:14:14

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

Humacyte Presents 2-Yr Results From V007 P...
11/10/2025 13:10:42

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups ...

Humacyte Publishes Study Showing Its Bioe...
10/30/2025 12:10:20

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

BTIG Maintains Buy on Humacyte, Lowers Pri...
10/13/2025 12:06:07

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $7 to $6.

12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

Humacyte Raises $60M In Oversubscribed Reg...
10/07/2025 13:05:18

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

D. Boral Capital Maintains Buy on Humacyte...
10/06/2025 18:01:20

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

Humacyte's Symvess Shows 100% Limb Salvage...
10/06/2025 13:29:48

- Results published in Oxford Academic's Military Medicine Journal -- After up to 18 months of follow-up patients were obse...

12 Health Care Stocks Moving In Friday's I...
10/03/2025 17:06:08

D. Boral Capital Maintains Buy on Humacyte...
09/30/2025 11:06:16

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

Humacyte Secures U.S. Patent For Bioengine...
09/29/2025 12:16:30

– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for im...

russell-2000-hits-all-time-highs-8-stocks-power-small-cap-comeback

Russell 2000 Hits All-Time Highs: 8 Stocks...
09/18/2025 19:08:11

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ta...

D. Boral Capital Maintains Buy on Humacyte...
09/18/2025 11:59:20

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

Humacyte Unveils Preclinical Success Of Bi...
09/18/2025 11:02:31

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

Humacyte Amends Revenue Interest Deal With...
09/18/2025 10:25:32

D. Boral Capital Maintains Buy on Humacyte...
09/15/2025 13:27:19

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.